ImmuneCyte Life Sciences Inc. said the company completed an acquisition of certain technologies to develop antibody therapies for COVID-19.

ImmuneCyte, which is a joint venture between ThermoGenesis Holdings Inc. and HealthBanks Biotech, acquired global intellectual property for four antibody drug candidates against SARS-CoV-2 — the virus that causes COVID-19 — and tools for screening and checking the efficacy of such antibodies.

ThermoGenesis said the antibodies, which were obtained from individuals who had recovered from COVID-19, and related technologies were originally developed by a research team affiliated with the East China Normal University.

Rancho Cordova, Calif.-based ThermoGenesis said it plans to use the newly acquired technologies with its diagnostic kits to identify people who have developed an immunity against the novel coronavirus and then isolate convalescent plasma and immune cells for potential anti-COVID-19 antibody development.

Under the agreement, ImmuneCyte paid an undisclosed amount up front and agreed to share future revenue from potential drugs under development.

ThermoGenesis noted in an April 13 press release that convalescent plasma therapy is an exploratory approach that involves giving patients an infusion of plasma from people who have recovered from COVID-19.

READ MORE: Sign up for our weekly coronavirus newsletter here, and read our latest coverage on the crisis here.